Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Lingxi Jiang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8070-5275; OpenAlex author ID A5035772816. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
77
Papers, trials and grants by year

2020: 2 papers · 2021: 3 papers · 2022: 4 papers · 2023: 6 papers · 2024: 5 papers · 2025: 4 papers · 2026: 1 paper

Papers 25

  1. Nimotuzumab Plus Gemcitabine-based Adjuvant Chemotherapy for Resectable Pancreatic Cancer: A Retrospective Observational Study. Co-author DOI 10.1097/mpa.0000000000002511↗
  2. CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. Last author DOI 10.1016/j.canlet.2025.217898↗
  3. TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.isci.2025.113060↗
  4. OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41467-025-62295-8↗
  5. Identification of a Novel Small Molecule STING Agonist Reshaping the Immunomicroenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/ijbs.107837↗
  6. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  7. Gasdermin C promotes Stemness and Immune Evasion in Pancreatic Cancer via Pyroptosis-Independent Mechanism. Co-author DOI 10.1002/advs.202308990↗
  8. Driver mutation subtypes involve with differentiated immunophenotypes influencing pancreatic cancer outcomes. Co-author DOI 10.1016/j.canlet.2024.217134↗
  9. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  10. Comprehensive analysis of KLF family reveals KLF6 as a promising prognostic and immune biomarker in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-024-03369-3↗
  11. Identification of a novel immune checkpoint molecule V-set immunoglobulin domain-containing 4 that leads to impaired immunity infiltration in pancreatic ductal… Co-author DOI 10.1007/s00262-023-03438-y↗
  12. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.1038/s41467-023-40314-w↗
  13. LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. Co-author DOI 10.1186/s12967-023-04702-6↗
  14. Retraction Note: The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Last author DOI 10.1186/s13045-023-01506-5↗
  15. Identification of COL12A1 as a novel diagnostic marker in pancreatic ductal adenocarcinoma by global proteome analysis Co-author DOI 10.21203/rs.3.rs-3037921/v1↗
  16. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… Co-author DOI 10.7150/thno.84978↗
  17. Cystatin B increases autophagic flux by sustaining proteolytic activity of cathepsin B and fuels glycolysis in pancreatic cancer: CSTB orchestrates autophagy a… Co-author DOI 10.1002/ctm2.1126↗
  18. The LINC00623/NAT10 signaling axis promotes pancreatic cancer progression by remodeling ac4C modification of mRNA. Last author DOI 10.1186/s13045-022-01338-9↗
  19. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Last author DOI 10.21203/rs.3.rs-1516835/v1↗
  20. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗
  21. Oncogene APOL1 promotes proliferation and inhibits apoptosis via activating NOTCH1 signaling pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03985-1↗
  22. Positive feedback between lncRNA FLVCR1-AS1 and KLF10 may inhibit pancreatic cancer progression via the PTEN/AKT pathway. Co-author DOI 10.1186/s13046-021-02097-0↗
  23. Tumor-associated macrophages promote pancreatic ductal adenocarcinoma progression by inducing epithelial-to-mesenchymal transition. Co-author DOI 10.18632/aging.202264↗
  24. Development and validation of a cancer stem cell-related signature for prognostic prediction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-020-02527-1↗
  25. Serum tRNA-derived small RNAs as potential novel diagnostic biomarkers for Pancreatic Ductal Adenocarcinoma Co-author DOI 10.21203/rs.3.rs-63978/v1↗

Closest collaborators

The 25 strongest of 77 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 16 shared papers, 2020–2026 · strength 2.81
  2. Chenghong Peng · 11 shared papers, 2020–2025 · strength 1.56
  3. Yizhi Cao · 8 shared papers, 2022–2025 · strength 1.37
  4. Meilin Xue · 8 shared papers, 2020–2025 · strength 1.20
  5. Hao Chen · 8 shared papers, 2020–2023 · strength 1.10
  6. Xiaxing Deng · 6 shared papers, 2020–2026 · strength 0.99
  7. Chenlei Wen · 5 shared papers, 2023–2026 · strength 0.94
  8. Hao Chen · 6 shared papers, 2021–2024 · strength 0.89
  9. Youwei Zhu · 6 shared papers, 2021–2024 · strength 0.88
  10. Lijie Han · 6 shared papers, 2022–2024 · strength 0.84
  11. Jiejie Qin · 4 shared papers, 2023–2025 · strength 0.78
  12. Cheng Xiong · 5 shared papers, 2021–2023 · strength 0.73
  13. Zengyu Feng · 5 shared papers, 2020–2023 · strength 0.68
  14. Kexian Li · 5 shared papers, 2020–2023 · strength 0.68
  15. Baiyong Shen · 4 shared papers, 2022–2025 · strength 0.65
  16. Shuyu Zhai · 4 shared papers, 2021–2025 · strength 0.64
  17. Qian Zhan · 3 shared papers, 2024–2026 · strength 0.60
  18. Yongsheng Jiang · 4 shared papers, 2021–2023 · strength 0.58
  19. Dongjie Chen · 3 shared papers, 2023–2025 · strength 0.57
  20. Yang Liu · 3 shared papers, 2024–2025 · strength 0.57
  21. Pengyi Liu · 3 shared papers, 2024–2025 · strength 0.57
  22. Kai Qin · 4 shared papers, 2022–2023 · strength 0.55
  23. Jiewei Lin · 4 shared papers, 2021–2022 · strength 0.51
  24. Xiaomei Tang · 3 shared papers, 2024–2025 · strength 0.50
  25. Jiaxin Luo · 3 shared papers, 2022–2025 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.